Paul Ivans
As payors and providers advance toward outcomes-based medicine, that shift is affecting pharmaceutical companies as well. As decisions about prescribing shift away from the doctor, who has been the primary recipient of pharma marketing for the past 20 years, to the C-level of integrated delivery networks (IDNs) and accountable care organizations (ACOs), pharma is going to have to...
